Swedish Orphan Biovitrum and Pharming sign Rhucin distribution agreement

19-Apr-2010 - Sweden

Swedish Orphan Biovitrum and Pharming Group NV announced an exclusive 10 year distribution agreement, under which Swedish Orphan Biovitrum will distribute Rhucin® in 24 EU countries, Norway, Iceland and Switzerland.

Under the agreement, Swedish Orphan Biovitrum will pay to Pharming an undisclosed upfront payment and a regulatory approval milestone. In addition, Swedish Orphan Biovitrum will pay a supply price that will include tiered performance based royalties to Pharming. Swedish Orphan Biovitrum will also have the right to participate in the future development and distribution of Rhucin® in the agreed countries for additional indications.

Rhucin® is a recombinant human C1 inhibitor for the acute treatment of Hereditary Angioedema (HAE) attacks. Pharming submitted an MAA for Rhucin® to the European Medicines Agency (EMA) in September 2009.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances